Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MHT RWD | Other Identifier | Alias Study Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to learn about how the commonly used menopausal hormone therapies were prescribed and taken in practice. This is done by using healthcare database, to study the overall dangers and benefits of menopausal hormone therapies in real-world practice.
This study will include subjects who were newly diagnosed menopausal symptoms between 2012 and 2019. They were all followed up for 12 months at least.
The study included the below subjects who:
The data collected will be used to understand:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Women with menopausal hormone therapy | Subjects who were newly diagnosed menopausal symptoms between 01 Jan 2012 and 31 Dec 2019, and were followed up for 12 months at least in the HIRA claims database |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Menopausal hormone therapy Intervention Type: Drug | Drug | Subjects who were newly diagnosed menopausal symptoms between 01 Jan 2012 and 31 Dec 2019, and were followed up for 12 months at least in the HIRA claims database |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Women Who Visited Hospitals for Menopausal Symptoms Distributed Per Year | Menopausal symptoms: at least one inpatient or outpatient claim with any of diagnosis codes based on Korean standard classification of disease, 8th revision(KCD-8):Korean version of ICD-10(International statistical classification of diseases and related health problems,10th revision), per protocol. N95.1: Menopausal, female climacteric states; N95.2:Postmenopausal atrophic vaginitis; N95.3:States associated with artificial menopause; N95.8 Other specified menopausal, perimenopausal disorders; N95.9: Menopausal, perimenopausal disorder, unspecified; M80.0: Postmenopausal osteoporosis with pathological fracture;M81.0: Postmenopausal osteoporosis; M81.99:Osteoporosis, unspecified, site unspecified; Osteopenia; M85.99: Disorder of bone density, structure, unspecified, site unspecified; Osteopenia, mild; Osteopenia, moderate; Osteopenia, severe. One participant could have visited hospital for >=1 time for different menopausal symptom. Index date: date of first prescription for MHT. | Date of diagnosis of menopausal symptom during inpatient/outpatient hospital visit; retrospective data observed in this study for approximately 6 months |
| Number of Women With MHT Use Distributed Per Year | Number of Women with MHT use distributed per year was reported in this outcome measure. One participant could have taken more than 1 type of MHT hence participants are not fully exclusive. Three types of MHT included ET (estrogen therapy), EPT (estrogen-progestin therapy), and tibolone. Index date was defined as the date of the first prescription for MHT. | Index Date; retrospective data observed in this study for approximately 6 months |
| Number of Participants According to Each Type of Menopausal Symptoms Distributed Per Year | Menopausal symptoms included vasomotor, bone and joint, genitourinary and psychosomatic. One participant could have more than 1 type of menopausal symptoms. Index date was defined as the date of the first prescription for MHT. | Date of diagnosis of menopausal symptom during inpatient/outpatient hospital visit; retrospective data observed in this study for approximately 6 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Subjects who were newly diagnosed menopausal symptoms between 01 Jan 2012 and 31 Dec 2019, and were followed up for 12 months at least in the HIRA claims database
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer South Korea | Seoul | South Korea |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Not provided
Not provided
Not provided
Not provided
Not provided
Data for female participants in South Korea, aged 40-59 years who had diagnosis of menopausal symptoms and/or received menopausal hormone therapy (MHT), was retrieved from Health Insurance and Review Assessment (HIRA) database from 1-January-2016 and 31-Decemeber-2020 (included follow-up duration). Retrospective available data was evaluated as per objectives of this study from 12-September-2023 to 11-March-2024 (approximately 6 months).
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | All Participants | Female participants aged 40-59 years who had diagnosis of menopausal symptoms and/or received MHT in real-world practice. No intervention was administered during this study. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Participants With MHT | Female participants aged 40-59 years who had diagnosis of menopausal symptoms and received MHT in real-world practice. No intervention was administered during this study. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Women Who Visited Hospitals for Menopausal Symptoms Distributed Per Year | Menopausal symptoms: at least one inpatient or outpatient claim with any of diagnosis codes based on Korean standard classification of disease, 8th revision(KCD-8):Korean version of ICD-10(International statistical classification of diseases and related health problems,10th revision), per protocol. N95.1: Menopausal, female climacteric states; N95.2:Postmenopausal atrophic vaginitis; N95.3:States associated with artificial menopause; N95.8 Other specified menopausal, perimenopausal disorders; N95.9: Menopausal, perimenopausal disorder, unspecified; M80.0: Postmenopausal osteoporosis with pathological fracture;M81.0: Postmenopausal osteoporosis; M81.99:Osteoporosis, unspecified, site unspecified; Osteopenia; M85.99: Disorder of bone density, structure, unspecified, site unspecified; Osteopenia, mild; Osteopenia, moderate; Osteopenia, severe. One participant could have visited hospital for >=1 time for different menopausal symptom. Index date: date of first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. | Posted | Count of Participants | Participants | Date of diagnosis of menopausal symptom during inpatient/outpatient hospital visit; retrospective data observed in this study for approximately 6 months |
Not applicable as adverse events and all-cause mortality were not planned to be evaluated for the study.
Due to non-interventional nature of the study and nature of data sources, the minimum criteria for reporting an adverse event (that is, identifiable participant, identifiable reporter, a suspect product, and event) could not be met, hence adverse events were not planned to be evaluated (thus at risk appears "0").
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Participants With MHT | Female participants aged 40-59 years who had diagnosis of menopausal symptoms and received MHT in real-world practice. No intervention was administered during this study. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Aug 2, 2023 | Mar 11, 2025 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D018488 | Bone Demineralization, Pathologic |
| ID | Term |
|---|---|
| D001851 | Bone Diseases, Metabolic |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Number of Participants According to Each Type of Menopausal Symptoms Per MHT | Menopausal symptoms included vasomotor symptoms, bone and joint symptoms, genitourinary symptoms, psychosomatic symptoms for systemic, Estrogen Therapy (ET), Estrogen-Progestin Therapy (EPT) and Tibolone. One participant could have more than 1 type of menopausal symptoms and have received more than 1 type of therapy. Index date was defined as the date of the first prescription for MHT. | Index Date; retrospective data observed in this study for approximately 6 months |
| Number of Participants With Use of Any MHT According to Age Group | Number of participants with use of any MHT according to age group were reported in this outcome measure. Index date was defined as the date of the first prescription for MHT. | Index Date; retrospective data observed in this study for approximately 6 months |
| Number of Participants With MHT According to Type of Administration | Number of participants with MHT according to type of administration were reported in this outcome measure. Type of administration included systemic hormone therapy (HT) (oral), systemic HT (transdermal), local HT (transvaginal). One participant could have received more than 1 type of therapy. Index date was defined as the date of the first prescription for MHT. | Index Date; retrospective data observed in this study for approximately 6 months |
| Percentage of Participants With Change in Treatment Regimen Change at Month 3 | Percentage of participants with change in treatment regimen at Month 3 were reported in this outcome measure. Data reported in this outcome measure included participants who received the treatments which included Systemic ET, EPT, Tibolone, Local ET and also participants with no treatment. Index date was defined as the date of the first prescription for MHT. | Month 3 post-index date; retrospective data observed in this study for approximately 6 months |
| Percentage of Participants With Change in Treatment Regimen Change at Month 6 | Percentage of participants with change in treatment regimen at Month 6 were reported in this outcome measure. Data reported in this outcome measure included participants who received the treatments which included Systemic ET, EPT, Tibolone, Local ET and also participants with no treatment. Index date was defined as the date of the first prescription for MHT. | Month 6 post-index date; retrospective data observed in this study for approximately 6 months |
| Percentage of Participants With Change in Treatment Regimen Change at Month 9 | Percentage of participants with change in treatment regimen at Month 9 were reported in this outcome measure. Data reported in this outcome measure included participants who received the treatments which included Systemic ET, EPT, Tibolone, Local ET and also participants with no treatment. Index date was defined as the date of the first prescription for MHT. | Month 9 post-index date; retrospective data observed in this study for approximately 6 months |
| Percentage of Participants With Change in Treatment Regimen Change at Month 12 | Percentage of participants with change in treatment regimen at Month 12 were reported in this outcome measure. Data reported in this outcome measure included participants who received the treatments which included Systemic ET, EPT, Tibolone, Local ET and also participants with no treatment. Index date was defined as the date of the first prescription for MHT. | Month 12 post-index date; retrospective data observed in this study for approximately 6 months |
| Time to Discontinuation of MHT | Time to discontinuation was defined as no subsequent prescriptions within 2 months of last prescription date. MHT included: Systemic MHT: ET, EPT, Tibolone and Local MHT: ET. Index date was defined as the date of the first prescription for MHT. | During 2 year of follow up from index date; retrospective data observed in this study for approximately 6 months |
| Time to Switching of MHT | Time to switching of MHT was reported in this outcome measure. Participants who switched the treatment classes were included. MHT included: Systemic MHT: ET, EPT, Tibolone and Local MHT: ET. Index date was defined as the date of the first prescription for MHT. | During 2 year of follow up from index date; retrospective data observed in this study for approximately 6 months |
| Percentage of Participants With Treatment Persistence at Month 3 Post-index According to Treatment Type | Treatment persistence was calculated by the average length of treatment of the drugs prescribed at the index date. Index date was defined as the date of the first prescription for MHT. | Month 3 post-index; retrospective data observed in this study for approximately 6 months |
| Percentage of Participants With Treatment Persistence at Month 6 Post-index According to Treatment Type | Treatment persistence was calculated by the average length of treatment of the drugs prescribed at the index date. Index date was defined as the date of the first prescription for MHT. | Month 6 post-index; retrospective data observed in this study for approximately 6 months |
| Percentage of Participants With Treatment Persistence at Month 9 Post-index According to Treatment Type | Treatment persistence was calculated by the average length of treatment of the drugs prescribed at the index date. Index date was defined as the date of the first prescription for MHT. | Month 9 post-index; retrospective data observed in this study for approximately 6 months |
| Percentage of Participants With Treatment Persistence at Month 12 Post-index According to Treatment Type | Treatment persistence was calculated by the average length of treatment of the drugs prescribed at the index date. Index date was defined as the date of the first prescription for MHT. | Month 12 post-index; retrospective data observed in this study for approximately 6 months |
| Mean Treatment Adherence (%) | Treatment adherence was evaluated using medication possession ratio (MPR), calculated as the total number of days of medication supply divided by the number of days in the follow-up period. Data for this outcome is expressed in percentage. Index date was defined as the date of the first prescription for MHT. | Index Date; retrospective data observed in this study for approximately 6 months |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
|
|
|
| Primary | Number of Women With MHT Use Distributed Per Year | Number of Women with MHT use distributed per year was reported in this outcome measure. One participant could have taken more than 1 type of MHT hence participants are not fully exclusive. Three types of MHT included ET (estrogen therapy), EPT (estrogen-progestin therapy), and tibolone. Index date was defined as the date of the first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. | Posted | Count of Participants | Participants | Index Date; retrospective data observed in this study for approximately 6 months |
|
|
|
| Primary | Number of Participants According to Each Type of Menopausal Symptoms Distributed Per Year | Menopausal symptoms included vasomotor, bone and joint, genitourinary and psychosomatic. One participant could have more than 1 type of menopausal symptoms. Index date was defined as the date of the first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. Here, 'Number Analyzed' signifies participants evaluable at specified rows. | Posted | Count of Participants | Participants | Date of diagnosis of menopausal symptom during inpatient/outpatient hospital visit; retrospective data observed in this study for approximately 6 months |
|
|
|
| Primary | Number of Participants According to Each Type of Menopausal Symptoms Per MHT | Menopausal symptoms included vasomotor symptoms, bone and joint symptoms, genitourinary symptoms, psychosomatic symptoms for systemic, Estrogen Therapy (ET), Estrogen-Progestin Therapy (EPT) and Tibolone. One participant could have more than 1 type of menopausal symptoms and have received more than 1 type of therapy. Index date was defined as the date of the first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. Here, 'Number Analyzed' signifies participants evaluable at specified rows. | Posted | Count of Participants | Participants | Index Date; retrospective data observed in this study for approximately 6 months |
|
|
|
| Primary | Number of Participants With Use of Any MHT According to Age Group | Number of participants with use of any MHT according to age group were reported in this outcome measure. Index date was defined as the date of the first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. | Posted | Count of Participants | Participants | Index Date; retrospective data observed in this study for approximately 6 months |
|
|
|
| Primary | Number of Participants With MHT According to Type of Administration | Number of participants with MHT according to type of administration were reported in this outcome measure. Type of administration included systemic hormone therapy (HT) (oral), systemic HT (transdermal), local HT (transvaginal). One participant could have received more than 1 type of therapy. Index date was defined as the date of the first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. | Posted | Count of Participants | Participants | Index Date; retrospective data observed in this study for approximately 6 months |
|
|
|
| Primary | Percentage of Participants With Change in Treatment Regimen Change at Month 3 | Percentage of participants with change in treatment regimen at Month 3 were reported in this outcome measure. Data reported in this outcome measure included participants who received the treatments which included Systemic ET, EPT, Tibolone, Local ET and also participants with no treatment. Index date was defined as the date of the first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. | Posted | Number | Percentage of participants | Month 3 post-index date; retrospective data observed in this study for approximately 6 months |
|
|
|
| Primary | Percentage of Participants With Change in Treatment Regimen Change at Month 6 | Percentage of participants with change in treatment regimen at Month 6 were reported in this outcome measure. Data reported in this outcome measure included participants who received the treatments which included Systemic ET, EPT, Tibolone, Local ET and also participants with no treatment. Index date was defined as the date of the first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. | Posted | Number | Percentage of participants | Month 6 post-index date; retrospective data observed in this study for approximately 6 months |
|
|
|
| Primary | Percentage of Participants With Change in Treatment Regimen Change at Month 9 | Percentage of participants with change in treatment regimen at Month 9 were reported in this outcome measure. Data reported in this outcome measure included participants who received the treatments which included Systemic ET, EPT, Tibolone, Local ET and also participants with no treatment. Index date was defined as the date of the first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. | Posted | Number | Percentage of participants | Month 9 post-index date; retrospective data observed in this study for approximately 6 months |
|
|
|
| Primary | Percentage of Participants With Change in Treatment Regimen Change at Month 12 | Percentage of participants with change in treatment regimen at Month 12 were reported in this outcome measure. Data reported in this outcome measure included participants who received the treatments which included Systemic ET, EPT, Tibolone, Local ET and also participants with no treatment. Index date was defined as the date of the first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. | Posted | Number | Percentage of participants | Month 12 post-index date; retrospective data observed in this study for approximately 6 months |
|
|
|
| Primary | Time to Discontinuation of MHT | Time to discontinuation was defined as no subsequent prescriptions within 2 months of last prescription date. MHT included: Systemic MHT: ET, EPT, Tibolone and Local MHT: ET. Index date was defined as the date of the first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. Here, 'Number Analyzed' signifies participants evaluable for specified rows. | Posted | Mean | Standard Deviation | Months | During 2 year of follow up from index date; retrospective data observed in this study for approximately 6 months |
|
|
|
| Primary | Time to Switching of MHT | Time to switching of MHT was reported in this outcome measure. Participants who switched the treatment classes were included. MHT included: Systemic MHT: ET, EPT, Tibolone and Local MHT: ET. Index date was defined as the date of the first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. Here, 'Number Analyzed' signifies participants evaluable for specified rows. | Posted | Mean | Standard Deviation | Months | During 2 year of follow up from index date; retrospective data observed in this study for approximately 6 months |
|
|
|
| Primary | Percentage of Participants With Treatment Persistence at Month 3 Post-index According to Treatment Type | Treatment persistence was calculated by the average length of treatment of the drugs prescribed at the index date. Index date was defined as the date of the first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. Here, 'Number Analyzed' signifies participants evaluable for specified rows. | Posted | Number | Percentage of participants | Month 3 post-index; retrospective data observed in this study for approximately 6 months |
|
|
|
| Primary | Percentage of Participants With Treatment Persistence at Month 6 Post-index According to Treatment Type | Treatment persistence was calculated by the average length of treatment of the drugs prescribed at the index date. Index date was defined as the date of the first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. Here, 'Number Analyzed' signifies participants evaluable for specified rows. | Posted | Number | Percentage of participants | Month 6 post-index; retrospective data observed in this study for approximately 6 months |
|
|
|
| Primary | Percentage of Participants With Treatment Persistence at Month 9 Post-index According to Treatment Type | Treatment persistence was calculated by the average length of treatment of the drugs prescribed at the index date. Index date was defined as the date of the first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. Here, 'Number Analyzed' signifies participants evaluable for specified rows. | Posted | Number | Percentage of participants | Month 9 post-index; retrospective data observed in this study for approximately 6 months |
|
|
|
| Primary | Percentage of Participants With Treatment Persistence at Month 12 Post-index According to Treatment Type | Treatment persistence was calculated by the average length of treatment of the drugs prescribed at the index date. Index date was defined as the date of the first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. Here, 'Number Analyzed' signifies participants evaluable for specified rows. | Posted | Number | Percentage of participants | Month 12 post-index; retrospective data observed in this study for approximately 6 months |
|
|
|
| Primary | Mean Treatment Adherence (%) | Treatment adherence was evaluated using medication possession ratio (MPR), calculated as the total number of days of medication supply divided by the number of days in the follow-up period. Data for this outcome is expressed in percentage. Index date was defined as the date of the first prescription for MHT. | Analysis population included all eligible participants who met inclusion/exclusion criteria, whose data were included and observed for evaluation in the study. Here, 'Number Analyzed' signifies participants evaluable for specified rows. | Posted | Mean | Standard Deviation | Percentage of days | Index Date; retrospective data observed in this study for approximately 6 months |
|
|
|
| 0 |
| 0 |
| 0 |
| 0 |
| 0 |
| 0 |
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| D009750 |
| Nutritional and Metabolic Diseases |
| Title | Measurements |
|---|
|
| 2019 |
|
|
| Genitourinary: 2016 |
|
|
| Psychosomatic: 2016 |
|
|
| Vasomotor: 2017 |
|
|
| Bone and joint: 2017 |
|
|
| Genitourinary: 2017 |
|
|
| Psychosomatic: 2017 |
|
|
| Vasomotor: 2018 |
|
|
| Bone and joint: 2018 |
|
|
| Genitourinary: 2018 |
|
|
| Psychosomatic: 2018 |
|
|
| Vasomotor: 2019 |
|
|
| Bone and joint: 2019 |
|
|
| Genitourinary: 2019 |
|
|
| Psychosomatic: 2019 |
|
|
|
| Systemic MHT: Genitourinary symptoms |
|
|
| Systemic MHT: Psychosomatic symptoms |
|
|
| ET: Vasomotor symptoms |
|
|
| ET: Bone and joint symptoms |
|
|
| ET: Genitourinary symptoms |
|
|
| ET: Psychosomatic symptoms |
|
|
| EPT: Vasomotor symptoms |
|
|
| EPT: Bone and joint symptoms |
|
|
| EPT: Genitourinary symptoms |
|
|
| EPT: Psychosomatic symptoms |
|
|
| Tibolone: Vasomotor symptoms |
|
|
| Tibolone: Bone and joint symptoms |
|
|
| Tibolone: Genitourinary symptoms |
|
|
| Tibolone: Psychosomatic symptoms |
|
|
| 55-59 Years |
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|
|
| Local ET |
|
| No treatment provided |
|
| Title | Measurements |
|---|
|
| Local ET |
|
| No treatment provided |
|
| Title | Measurements |
|---|
|
| Local ET |
|
| No treatment provided |
|
| Title | Measurements |
|---|
|
| Local ET |
|
| No treatment provided |
|
|
| Systemic MHT: Tibolone |
|
|
| Local MHT: ET |
|
|
|
| Systemic MHT: Tibolone |
|
|
| Local MHT: ET |
|
|
|
| Systemic MHT: Tibolone |
|
|
| Local MHT: ET |
|
|
|
| Systemic MHT: Tibolone |
|
|
| Local MHT: ET |
|
|
|
| Systemic MHT: Tibolone |
|
|
| Local MHT: ET |
|
|
|
| Systemic MHT: Tibolone |
|
|
| Local MHT: ET |
|
|
|
| Systemic MHT: Tibolone |
|
|
| Local MHT: ET |
|
|